Pharmacological targeting of FXR by the semi-synthetic BA Obeticholic acid, a drug that is already in clinical for the treatment of primary biliary cholangitis (PBC), has been shown to counteract the intestinal inflammatory response in chemically-induced murine models of colitis, beneficial effects that are absent in FXR−/− mice [23]. This evidence concerns the gene NR1H4 and primary biliary cholangitis.